Market Overview

On Tuesday 20 October, the shares of Pharvaris NV (ticker 9EN.F) experienced a significant decline, falling 6.98 % during the 24‑hour period ending at 22:57 Central European Time. At the close, the stock traded at approximately EUR 27.50 on the Frankfurt Stock Exchange, reflecting a broader downward trend that has seen the company’s share price drop 25.3 % since the end of September.

The current circulating supply of Pharvaris shares stands at 70.2 million, and the market capitalization is EUR 1.70 billion. In the last 24 hours, a total of EUR 739.5 million worth of Pharvaris shares exchanged hands. The 200‑day simple moving average sits just below the current price, at EUR 26.48, indicating that the stock is trading slightly above its long‑term average but remains vulnerable to further corrections.

Historical price extremes provide context for the present movement: the highest price over the preceding 52 weeks was EUR 38.25, recorded on 9 August 2026, while the lowest price in the same period was EUR 18.30, observed on 7 November 2025.

The 24‑hour performance of other stocks in the same sector and region illustrates a mixed landscape:

  • Acomo NV (ACOMO.AS) – down 0.22 %, trading at EUR 23.15. The company’s market capitalization is EUR 683.2 million, with a price‑to‑earnings ratio of 11.67.
  • Amg Critical Materials NV (AMG.AS) – down 3.72 %, at EUR 24.36. Market capitalization of EUR 921.7 million and a high price‑to‑earnings ratio of 173.46, reflecting elevated valuation expectations.
  • Oci (OCI.AS) – flat, unchanged at EUR 4.15. Market capitalization of EUR 875.5 million.
  • Uniqure (UQ1.F) – up 3.01 %, trading at EUR 19.52. Market capitalization of EUR 1.40 billion.
  • Basic‑fit (BFIT.AS) – up 0.4 %, at EUR 31.20. Market capitalization of EUR 2.00 billion and a price‑to‑earnings ratio of 42.83.

These figures suggest that while some peers have maintained or modestly increased their valuations, Pharvaris is experiencing a sharper decline, likely driven by sector‑specific dynamics and investor sentiment toward clinical‑stage pharmaceutical ventures.

Company Profile

Pharvaris NV is a clinical‑stage biotechnology firm headquartered in Leiden, Netherlands, with a strong presence in both the Dutch and Swiss markets. The company focuses on discovering and developing novel oral β₂‑receptor antagonists aimed at treating various patient populations. Its products are intended to fill unmet medical needs, positioning Pharvaris as a potential player in niche therapeutic areas.

The firm is listed on the Frankfurt Stock Exchange, and its official website is accessible at www.pharvaris.com . Investors and analysts will be monitoring the company’s clinical trial milestones and regulatory filings closely, as these factors are critical determinants of future valuation and market performance.

Outlook

Given the current decline and the recent volatility in comparable stocks, stakeholders should be cautious. The company’s clinical‑stage status inherently carries high risk, and the near‑term trajectory of its share price will likely be influenced by forthcoming clinical data, partnership announcements, and broader market conditions in the life‑sciences sector.